Mesoblast Future Growth
Future criteria checks 5/6
Mesoblast is forecast to grow earnings and revenue by 61.5% and 46% per annum respectively. EPS is expected to grow by 94.4% per annum. Return on equity is forecast to be 15.5% in 3 years.
Key information
61.5%
Earnings growth rate
94.4%
EPS growth rate
Biotechs earnings growth | 15.5% |
Revenue growth rate | 46.0% |
Future return on equity | 15.5% |
Analyst coverage | Good |
Last updated | 03 Dec 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 463 | 106 | 87 | 163 | 5 |
6/30/2026 | 234 | -13 | -48 | 37 | 6 |
6/30/2025 | 17 | -81 | -67 | -60 | 5 |
6/30/2024 | 6 | -88 | -49 | -48 | N/A |
3/31/2024 | 7 | -82 | -54 | -54 | N/A |
12/31/2023 | 7 | -73 | -59 | -59 | N/A |
9/30/2023 | 8 | -81 | -62 | -62 | N/A |
6/30/2023 | 8 | -82 | -64 | -63 | N/A |
3/31/2023 | 8 | -81 | -61 | -61 | N/A |
12/31/2022 | 8 | -84 | -60 | -60 | N/A |
9/30/2022 | 8 | -86 | -62 | -62 | N/A |
6/30/2022 | 10 | -91 | -66 | -66 | N/A |
3/31/2022 | 10 | -92 | -71 | -71 | N/A |
12/31/2021 | 10 | -97 | -81 | -80 | N/A |
9/30/2021 | 10 | -97 | -92 | -91 | N/A |
6/30/2021 | 7 | -99 | -102 | -101 | N/A |
3/31/2021 | 6 | -109 | -104 | -101 | N/A |
12/31/2020 | 16 | -98 | -99 | -97 | N/A |
9/30/2020 | 16 | -97 | -71 | -69 | N/A |
6/30/2020 | 32 | -78 | -59 | -56 | N/A |
3/31/2020 | 33 | -66 | -57 | -56 | N/A |
12/31/2019 | 22 | -76 | -58 | -57 | N/A |
9/30/2019 | 22 | -76 | -54 | -54 | N/A |
6/30/2019 | 17 | -90 | -58 | -58 | N/A |
3/31/2019 | 16 | -90 | -59 | -59 | N/A |
12/31/2018 | 16 | -86 | -57 | -57 | N/A |
9/30/2018 | 28 | -48 | -74 | -74 | N/A |
6/30/2018 | 17 | -35 | -75 | -75 | N/A |
3/31/2018 | 16 | -42 | N/A | -78 | N/A |
12/31/2017 | 16 | -30 | N/A | -84 | N/A |
9/30/2017 | 3 | -64 | N/A | -95 | N/A |
6/30/2017 | 2 | -77 | N/A | -95 | N/A |
3/31/2017 | 29 | -1 | N/A | -90 | N/A |
12/31/2016 | 32 | -8 | N/A | -86 | N/A |
9/30/2016 | 35 | -11 | N/A | -81 | N/A |
6/30/2016 | 43 | -4 | N/A | -88 | N/A |
3/31/2016 | 20 | -83 | N/A | -97 | N/A |
12/31/2015 | 20 | -88 | N/A | -98 | N/A |
9/30/2015 | 20 | -94 | N/A | -101 | N/A |
6/30/2015 | 20 | -96 | N/A | -101 | N/A |
3/31/2015 | 21 | -85 | N/A | -87 | N/A |
12/31/2014 | 24 | -84 | N/A | -78 | N/A |
9/30/2014 | 26 | -75 | N/A | -80 | N/A |
6/30/2014 | 23 | -76 | N/A | -75 | N/A |
3/31/2014 | 30 | -68 | N/A | -73 | N/A |
12/31/2013 | 35 | -58 | N/A | -69 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MSB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MSB is expected to become profitable in the next 3 years.
Revenue vs Market: MSB's revenue (46% per year) is forecast to grow faster than the Australian market (5.8% per year).
High Growth Revenue: MSB's revenue (46% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MSB's Return on Equity is forecast to be low in 3 years time (15.5%).